Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta‐analysis and network meta‐analysis
European Journal of Neurology · 2023-12 · 30 (12) · 3854-3867
DOI: 10.1111/ene.15872 ↗At a glance
Systematische Übersicht in European Journal of Neurology, published online on 2023-05-30. Written by Francesco Saccà and 4 co-authors. Institution: Department of Neurosciences and Reproductive and Odontostomatological Sciences, University "Federico II", Naples, Italy. Major MEDLINE topics: Activities of Daily Living, Myasthenia Gravis. Cited 81 times so far (Crossref); 42 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background and purpose Therapy for myasthenia gravis (MG) is undergoing a profound change, with new treatments being tested. These include complement inhibitors and neonatal Fc receptor (FcRn) blockers. The aim of this study was to perform a meta‐analysis and network meta‐analysis of randomized and placebo‐controlled trials of innovative therapies in MG with available efficacy data.
Methods
We assessed statistical heterogeneity across trials based on the Cochrane Q test and I 2 values, and mean differences were pooled using the random‐effects model. Treatment efficacy was assessed after 26 weeks of eculizumab and ravulizumab, 28 days of efgartigimod, 43 days of rozanolixizumab, 12 weeks of zilucoplan, and 16, 24 or 52 weeks of rituximab treatment.
Results
We observed an overall mean Myasthenia Gravis‐Activities of Daily Living scale (MG‐ADL) score change of −2.17 points (95% confidence interval [CI] −2.67, −1.67; p < 0.001) as compared to placebo. No significant difference emerged between complement inhibitors and anti‐FcRn treatment ( p = 0.16). The change in Quantitative Myasthenia Gravis scale (QMG) score was −3.46 (95% CI −4.53, −2.39; p < 0.001), with a higher reduction with FcRns (−4.78 vs. −2.60; p < 0.001). Rituximab did not significantly improve the MG‐ADL (−0.92 [95% CI −2.24, 0.39]; p = 0.17) or QMG scores (−1.9 [95% CI −3.97, 0.18]; p = 0.07). In the network meta‐analysis, efgartigimod had the highest probability of being the best treatment, followed by rozanolixizumab.
Conclusion
Anti‐complement and FcRn treatments both proved to be effective in MG patients, whereas rituximab did not show a significant benefit for patients. Within the limitations of this meta‐analysis, including efficacy time points, FcRn treatments showed a greater effect on QMG score in the short term. Real‐life studies with long‐term measurements are needed to confirm our results.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurosciences and Reproductive and Odontostomatological Sciences, University "Federico II", Naples, Italy.
- Department of Health Sciences, University of Genoa, Genoa, Italy.
ORCID profiles: Francesco Saccà
Cite
APA
Saccà, F., Pane, C., Espinosa, P. E., Sormani, M. P., & Signori, A. (2023). Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta‐analysis and network meta‐analysis. European Journal of Neurology, 30(12), 3854-3867. https://doi.org/10.1111/ene.15872
Vancouver
Saccà F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta‐analysis and network meta‐analysis. European Journal of Neurology. 2023;30(12):3854-3867. doi:10.1111/ene.15872
BibTeX
@article{Sacc2023,
author = {Saccà, Francesco and Pane, Chiara and Espinosa, Pablo Ezequiel and Sormani, Maria Pia and Signori, Alessio},
title = {Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta‐analysis and network meta‐analysis},
journal = {European Journal of Neurology},
year = {2023},
volume = {30},
number = {12},
pages = {3854--3867},
doi = {10.1111/ene.15872}
}
EUVIMED